These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 22566214)
1. Successful collection and engraftment of autologous peripheral blood progenitor cells in poorly mobilized patients receiving high-dose granulocyte colony-stimulating factor. Cooper DL; Proytcheva M; Medoff E; Seropian SE; Snyder EL; Krause DS; Wu Y J Clin Apher; 2012 Nov; 27(5):235-41. PubMed ID: 22566214 [TBL] [Abstract][Full Text] [Related]
2. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor. Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358 [TBL] [Abstract][Full Text] [Related]
3. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017 [TBL] [Abstract][Full Text] [Related]
4. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor. Ford CD; Greenwood J; Anderson J; Snow G; Petersen FB Transfusion; 2006 Feb; 46(2):193-8. PubMed ID: 16441594 [TBL] [Abstract][Full Text] [Related]
5. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983 [TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
7. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715 [TBL] [Abstract][Full Text] [Related]
8. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
9. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420 [TBL] [Abstract][Full Text] [Related]
10. Correlations between hematopoietic progenitor cell counts as measured by Sysmex and CD34+ cell harvest yields following mobilization with different regimens. Vogel W; Kopp HG; Kanz L; Einsele H J Cancer Res Clin Oncol; 2002 Jul; 128(7):380-4. PubMed ID: 12136252 [TBL] [Abstract][Full Text] [Related]
11. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF]. Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058 [TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253 [TBL] [Abstract][Full Text] [Related]
13. G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation. Seshadri T; Al-Farsi K; Stakiw J; Ma C; Saragosa R; Franke N; Keating A; Crump M; Kuruvilla J Bone Marrow Transplant; 2008 Dec; 42(11):733-7. PubMed ID: 18711349 [TBL] [Abstract][Full Text] [Related]
14. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278 [TBL] [Abstract][Full Text] [Related]
16. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor. Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727 [TBL] [Abstract][Full Text] [Related]
17. Defining "poor mobilizer" in pediatric patients who need an autologous peripheral blood progenitor cell transplantation. Sevilla J; Guillén M; Castillo A; Prudencio M; González-Vicent M; Lassaletta Á; Cormenzana M; Ramírez M; Pérez-Martínez A; Madero L; Díaz-Pérez MÁ Cytotherapy; 2013 Jan; 15(1):132-7. PubMed ID: 23260093 [TBL] [Abstract][Full Text] [Related]
19. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321 [TBL] [Abstract][Full Text] [Related]
20. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg). Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]